Verismo Licenses Stanford's In-Body CAR-T Platform
The licensing deal gives Verismo rights to a technology that generates CAR-T cells inside the patient's body.
Updated on Nov. 18, 2026 in Biotech

Verismo Therapeutics, the U.S. subsidiary of HLB Innovation, has entered a licensing agreement with Stanford University School of Medicine for its PACK-IT platform technology. PACK-IT generates CAR-T cells within the body rather than requiring T-cells to be extracted, modified and reinfused.
Why it matters
Conventional CAR-T therapies involve complex procedures that take weeks and carry high treatment costs. An in-body approach could simplify delivery of this cancer treatment, and Verismo plans to apply the technology to its KIR-CAR platform.
PACK-IT uses viral particles to deliver genetic material that introduces CAR genes into T-cells inside the patient. Preclinical data presented at AACR last year showed superior efficacy over the conventional lentivirus method, but clinical results remain unreported.
The players
Verismo Therapeutics
Verismo Therapeutics is a U.S. biotechnology subsidiary of HLB Innovation focused on in-body CAR-T cell therapies.
Stanford University School of Medicine
Stanford University School of Medicine is a leading academic medical institution whose researchers developed the PACK-IT platform.
HLB Innovation
HLB Innovation is the parent company of Verismo Therapeutics and oversees its U.S. operations.
The details
PACK-IT was developed by Professor Crystal Mackall's research team at Stanford University School of Medicine. Verismo is currently running Phase 1 clinical trials for solid tumor and B-cell malignancy candidates based on its KIR-CAR platform.
Timeline
Preclinical PACK-IT results were presented at AACR last year.
The licensing agreement with Stanford was announced on November 18, 2026.
The Tech Race
The licensing deal positions Verismo against developers still relying on the ex vivo model that requires extracting, engineering and reinfusing a patient's T-cells. Moving cell engineering inside the body is a departure from the lentivirus-based approach that has defined commercial CAR-T therapies.
If in-body CAR-T therapies reach patients, they could reduce the weeks-long manufacturing process and the complex procedures associated with conventional treatment. Any clinical use would depend on results from ongoing Phase 1 trials and regulatory approval, which have not yet been reported.
The takeaway
The shift from extracting and reinfusing cells to generating CAR-T cells in the body could change how CAR-T therapies are delivered, though clinical evidence in patients is still pending.
Further reading
For related coverage of advances in cell and gene therapy, explore more Biotech reporting.






